Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
9 evidence topics · 7 sources
BOND-003 Cohort C: complete response in second-line and chemotherapy-pretreated subgroups
BOND-003 Cohort C: subgroup consistency and response after re-induction
BOND-003 Cohort C: cystectomy-free survival across subgroups
Comparator trial: TAR-200 by presence of papillary disease and T stage
“Subgroup analyses showed consistently high CR rates across all clinically relevant subgroups, including patients with and without concurrent papillary disease (82.1% and 82.5%, respectively; Data Supplement, Fig S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twelve-month DFS rates were consistent in patients with high-grade Ta and T1 disease (70.0% [95% CI, 44.8 to 85.4] and 72.2% [95% CI, 44.8 to 87.6], respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator trials: carcinoma in situ cohorts and papillary-only cohorts
Systematic reviews: predictors of response after BCG failure
Regulatory guidance on stratification by tumor pattern
Variable enrollment criteria across BCG-unresponsive trials
“Of 31 trials, 15 (48%) had inclusion/exclusion criteria that were fully consistent with (inclusive of patients that met) the BCG unresponsive bladder cancer definition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common disease specific exclusion for patients with BCG unresponsive bladder cancer was a requirement for stage Tis (carcinoma in situ, CIS), which pertained to 7 (23%) of trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For bladder cancer treating physicians and regulatory bodies, this also hinders comparisons across agents.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote